



ICI PAKISTAN LTD.

ICI House, 5 West Wharf,
Karachi 74000

T +92 21 3231 3717-22
F +92 21 3231 1739
UAN 111 100 200

www.ici.com.pk

The General Manager
Pakistan Stock Exchange Limited
Stock Exchange Building,
Stock Exchange Road,
Karachi – 74000

Ref # ComSec/PSX/23/2017
May 19, 2017

Subject: Disclosure of Material Information – Signing of Transaction Agreements

Dear Sir,

This is further to our letter bearing Ref No. ComSec/PSX/12/2017 dated March 3, 2017, in relation to the purchase of a manufacturing facility owned by Wyeth Pakistan Limited ('Wyeth'), located at S-33, Hawkes Bay Road, S.I.T.E. Karachi, along with acquisition of (i) Wyeth's products and registrations, consisting of Entox-P; Lederplex; Lederrif; Mucaine; Nilstat; Tri-Hemic; and Wymox, and (ii) Pfizer Pakistan Limited's products and registration, namely Citralka and Combatrin (together as "the Assets").

Pursuant to Sections 96 and 131 of the Securities Act, 2015 and Clause 5.19.13(c) of the Rule Book of the Pakistan Stock Exchange, we hereby inform you that ICI Pakistan Limited (as the 'Purchaser') and each of Wyeth, Pfizer Pakistan Limited, Pfizer Inc., and Wyeth LLC (as 'Sellers') have entered into the Asset Purchase Agreements as of May 19, 2017, recording terms and conditions for the proposed sale of the Assets by the Sellers and its acquisition by the Purchaser, at an aggregate purchase price of PKR 1.91 billion (APAs). The completion of the transaction contemplated in the APAs will remain subject to satisfaction of conditions precedent and regulatory approvals specified therein.

A disclosure form as required under S.R.O.143(1)/2012 dated December 5, 2012 read with Section 131 of the Securities Act, 2015 is also enclosed as **Annexure – 'A'**.

Sincerely,

Saima Kamila Khan
Company Secretary

cc: The Commissioner
Company Law Division, Securities & Exchange Commission of Pakistan
NIC Building, Jinnah Avenue, Islamabad.

The Commissioner
Securities Market Division, Securities & Exchange Commission of Pakistan
NIC Building, Jinnah Avenue, Islamabad.



DISCLOSURE FORM

IN TERMS OF SECTIONS 96 AND 131 OF THE SECURITIES ACT, 2015

Name of Company:	ICI Pakistan Limited ICI House, 5 West Wharf, Karachi.
Date of Report:	May 19, 2017
Contact Information:	Saima Kamila Khan Company Secretary ICI House, 5 West Wharf, Karachi. Telephone Number: +9221-111-100-200 (Ext- 8114) Fax Number: +92 21 32312500

[X] Public disclosure of price sensitive / inside information, which directly concerns the listed securities.

Disclosure of price sensitive/inside information by listed company.

This is further to our letter bearing Ref No. ComSec/PSX/12/2017 dated March 3, 2017, in relation to the purchase of a manufacturing facility owned by Wyeth Pakistan Limited ('Wyeth'), located at S-33, Hawkes Bay Road, S.I.T.E. Karachi, along with acquisition of (i) Wyeth's products and registrations, consisting of Entox-P; Lederplex; Lederrif; Mucaine; Nilstat; Tri-Hemic; and Wymox, and (ii) Pfizer Pakistan Limited's products and registration, namely Citralca and Combatrin (together as "the Assets").

Pursuant to Sections 96 and 131 of the Securities Act, 2015 and Clause 5.19.13(c) of the Rule Book of the Pakistan Stock Exchange, we hereby inform you that ICI Pakistan Limited (as the 'Purchaser') and each of Wyeth, Pfizer Pakistan Limited, Pfizer Inc., and Wyeth LLC (as 'Sellers') have entered into the Asset Purchase Agreements as of May 19, 2017, recording terms and conditions for the proposed sale of the Assets by the Sellers and its acquisition by the Purchaser, at an aggregate purchase price of PKR 1.91 billion (APAs). The completion of the transaction contemplated in the APAs will remain subject to satisfaction of conditions precedent and regulatory approvals specified therein."

The Company has duly caused this form / statement to be signed on its behalf by the undersigned hereunto duly authorized.

Sincerely,

Saima Kamila Khan
Company Secretary